Molecular Resistance Mechanisms in Plasmodium falciparum Malaria

Plasmodium falciparum has evolved a suite of molecular adaptations that undermine the efficacy of frontline antimalarial drugs. Central among these are point mutations in the dihydrofolate reductase and dihydropteroate synthase enzymes, which reduce binding affinity for sulphadoxine–pyrimethamine. Alterations in the chloroquine resistance transporter and multidrug resistance protein 1 disrupt drug accumulation in parasite digestive vacuoles, compromising aminoquinoline and artemisinin partner compounds. Amplification of transporter gene copies and emerging single-nucleotide polymorphisms in novel loci further expand the parasite’s resistance repertoire. Whole-genome sequencing has revealed marked regional heterogeneity in resistance allele frequencies, shaped by local drug use patterns and transmission intensity. The circulation of resistant haplotypes between human and mosquito hosts sustains and spreads these adaptations. A detailed understanding of these mechanisms is essential for refining surveillance, guiding the development of next-generation therapeutics and optimising chemoprevention strategies on a global scale.

Research from Nature Portfolio

Recent studies have harnessed continent-wide genomic datasets to characterise antifolate resistance in unprecedented detail. One investigation of several thousand parasite genomes confirmed the persistent dominance of the triple-mutant dihydrofolate reductase haplotype across Africa, while revealing pronounced spatial variability in dihydropteroate synthase variants linked to regional drug pressure. This work highlighted that key substitutions such as K540E and A581G exhibit heterogeneous distributions, underscoring the need for region-specific monitoring thresholds. Complementary research introduced advanced statistical models to infer true parasite haplotype frequencies from mixed-infection surveys. These models revealed that resistant clones spread more rapidly once they exceed critical frequency thresholds, thereby informing tailored interventions and policy decisions.

Molecular Resistance Mechanisms in Plasmodium falciparum Malaria publication trend

The graph below shows the total number of articles in molecular resistance mechanisms in plasmodium falciparum malaria across all publications each year (not limited to Nature Index journals).

Technical terms

Haplotype: A group of genetic variants at adjacent loci on the same chromosome that are inherited together.

Single-nucleotide polymorphism (SNP): A single-base variation in the DNA sequence that can affect protein function or gene regulation.

Dihydrofolate reductase (dhfr): An enzyme involved in folate metabolism and the target of pyrimethamine in antimalarial therapy.

Dihydropteroate synthase (dhps): An enzyme in the folate synthesis pathway targeted by sulphadoxine, where mutations confer drug resistance.

Allele frequency: The proportion of chromosomes in a population that carry a specific genetic variant.

References

1. Prevalence of molecular markers of resistance to sulfadoxine–pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation. The Lancet Global Health (2023).
2. Geographical emergence of sulfadoxine-pyrimethamine drug resistance-associated P. falciparum and P. malariae alleles in co-existing Anopheles mosquito and asymptomatic human populations across Cameroon. Antimicrobial Agents and Chemotherapy (2023).
3. Disparate co-evolution and prevalence of sulfadoxine and pyrimethamine resistance alleles and haplotypes at dhfr and dhps genes across Africa. Scientific Reports (2025).
4. A spatio-temporal model of multi-marker antimalarial resistance. Journal of The Royal Society Interface (2024).